Inhibition of Wnt/β-Catenin Signaling Sensitizes Esophageal Cancer Cells to Chemoradiotherapy

Int J Mol Sci. 2021 Sep 24;22(19):10301. doi: 10.3390/ijms221910301.

Abstract

The standard treatment of locally advanced esophageal cancer comprises multimodal treatment concepts including preoperative chemoradiotherapy (CRT) followed by radical surgical resection. However, despite intensified treatment approaches, 5-year survival rates are still low. Therefore, new strategies are required to overcome treatment resistance, and to improve patients' outcome. In this study, we investigated the impact of Wnt/β-catenin signaling on CRT resistance in esophageal cancer cells. Experiments were conducted in adenocarcinoma and squamous cell carcinoma cell lines with varying expression levels of Wnt proteins and Wnt/β-catenin signaling activities. To investigate the effect of Wnt/β-catenin signaling on CRT responsiveness, we genetically or pharmacologically inhibited Wnt/β-catenin signaling. Our experiments revealed that inhibition of Wnt/β-catenin signaling sensitizes cell lines with robust pathway activity to CRT. In conclusion, Wnt/β-catenin activity may guide precision therapies in esophageal carcinoma patients.

Keywords: Wnt/β-catenin pathway; chemoradiotherapy; chemoradiotherapy-sensitization; esophageal cancer; tankyrase inhibition; treatment resistance.

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / therapy
  • Cell Line, Tumor
  • Chemoradiotherapy / methods
  • Drug Resistance, Neoplasm / genetics*
  • Esophageal Neoplasms / genetics*
  • Esophageal Neoplasms / therapy*
  • Esophageal Squamous Cell Carcinoma / genetics
  • Esophageal Squamous Cell Carcinoma / therapy
  • Humans
  • Wnt Proteins / genetics*
  • Wnt Signaling Pathway / genetics*
  • beta Catenin / genetics*

Substances

  • CTNNB1 protein, human
  • Wnt Proteins
  • beta Catenin